CAMBRIDGE, Mass.--(BUSINESS WIRE)--Rheos Medicines, a biopharmaceutical company harnessing insights in immunometabolism to create a new class of therapeutics for patients with severe immune-mediated diseases, announced today that Dania Rabah, Ph.D., has been hired as the company’s Chief Scientific Officer.
“Rheos is delighted to welcome Dania to our team. Her deep knowledge of immunology, coupled with her extensive experience building research teams and advancing programs from inception through clinical proof of concept, makes her an ideal addition to our rapidly growing company,” said Barbara Fox, Ph.D., President and CEO.
Dr. Rabah brings to Rheos more than 15 years’ experience building and leading teams of scientists in drug discovery and early development. Dr. Rabah served as the Head of the Drug Discovery Incubator, Research and Early Development at Biogen. She and her team created a robust and innovative pipeline, advanced programs across multiple therapeutic areas and treatment modalities, advanced therapeutic area strategies to support development, and implemented research operating model improvements to support a biology and target driven development approach. She also brings extensive experience in immunology drug development, having advanced candidates all the way from program initiation through Phase 2 clinical proof of concept. Dania earned her Ph.D. in Microbiology and Immunology from Virginia Commonwealth University/Medical College of Virginia, and a MS in Human Morphology and Immunology and a BS in Biology from the American University of Beirut. She completed her post-doctoral training in Immunology at Harvard Medical School.
“Immunometabolism serves as a framework to both identify novel target biology and develop a superior understanding of immune-mediated disease,” said Dr. Rabah. “I am thrilled to join this exciting team, and to help lead the translation of these insights into new medicines to meet the needs of patients.”
About Rheos Medicines
Rheos Medicines is a biopharmaceutical company harnessing insights in immunometabolism to develop novel therapeutics for patients with severe immune-mediated diseases. Our approach targets the underlying intracellular metabolism of immune cells and has the potential to unlock a new frontier in drug discovery for immune-mediated disease. Through a proprietary platform and product engine that integrates multiple “omic” datasets, we systematically define the biologic links between immune cell metabolism and function and simultaneously identify new drug targets and biomarkers of disease to bring precision to the treatment of immune-mediated diseases. We have assembled leading scientists whose discoveries opened the field of immunometabolism, clinicians with a deep understanding of immune-mediated diseases, and an experienced biotech leadership team. Rheos was founded by Third Rock Ventures and is located in Cambridge, MA. For more information, please visit www.rheosrx.com.